Antimeningococcal Protection in Patients Receiving Terminal Complement Inhibitors

Introduction: C5 inhibitor (C5i) therapy markedly increases susceptibility to invasive meningococcal disease (IMD) by blocking the terminal complement pathway essential for defense against Neisseria meningitidis. Vaccination is recommended for all recipients, yet breakthrough infections persist. Ant...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Aleksandra Vujović, Franz Schaefer, Anne-Laure Sellier-Leclerc, Mattia Parolin, Víctor Pérez-Beltrán, Jonas Hofstetter, Olivia Boyer, Maria Cristina Mancuso, Sandra Habbig, Tanja Kersnik Levart, Klaus Arbeiter, Fabian Eibensteiner, Lovro Lamot, Justine Bacchetta, Lisa Condamine, Dounia Habchi, Lydia Slimani, Amina Talhi, Sacha Flammier, Marc Fila, Julie Tenenbaum, Laurence Heidet, Kahina Saidoun, Nabila Moussaoui, Stefan Kohl, Susanne Schaefer, Jose Antonio Ramirez Garcia, Marcus Weitz, Kathrin Buder, Lena Lechler, Matko Marlais, Orsolya Horváth, Giovanni Montini, Francesco Trepiccione, Miriam Zacchia, Germana Longo, Nicola Bertazza Partigiani, Antonio Gargiulo, Chiara Bettini, Vitor Hugo Martins, Aleksandra Zurowska, Magdalena Drozynska-Duklas, Anna Krakowska, Joaquim Calado, Rute Baeta Baptista, Ana Teixeira, Anca Marin, Valentin Mocanu, Andreja Aleš Rigler, Tomaž Šimnovec, Carla Soto, Romy Bouwmeester, Eiske Dorresteijn
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2026-02-01
סדרה:	Kidney International Reports
נושאים:	antibiotic prophylaxis antimeningococcal protection antimeningococcal vaccination atypical hemolytic uremic syndrome complement inhibitors meningococcal infection
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2468024925007107
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!